Last updated: February 17, 2026
Overview
NDC 54738-0980 corresponds to Vistogard (uridine triacetate), a rare anti-metabolite agent approved by the FDA in 2015. It is indicated for the empirical treatment of acute radiation or chemotherapy drug-induced emergency overdose of fluorouracil or capecitabine. The drug plays a critical role in managing life-threatening toxicity, making its market primarily confined to hospital and emergency care settings.
Market Size and Demand Drivers
Indication and Usage
Vistogard’s market is limited to overdose cases of fluorouracil or capecitabine, both used in chemotherapy regimens. These drugs are standard cancer treatments, with an estimated 1.8 million chemotherapies administered annually in the U.S. (SEER Program, 2021). The incidence of overdose or severe toxicity is low but critical, occurring in approximately 0.2%–0.3% of administrations, according to clinical studies (Johnson & Cummings, 2018).
Market Penetration
- Limited by medical emergency nature; dosing is episodic.
- Usage depends on the prevalence of fluorouracil or capecitabine therapy, estimated at 40,000 to 45,000 annual overdose cases in the US.
- International markets reflect similar patterns, especially in Europe where fluorouracil ranks as a standard treatment.
Competitive Landscape
- No direct generic competition exists; Vistogard remains the sole FDA-approved antidote.
- Alternative off-label treatments are not established.
- The price in the US influences global pricing, especially in markets without local approvals.
Pricing Trends
Current US Pricing
- Wholesale acquisition cost (WAC): Approximately $19,350 per treatment course (Medicare Part B data, 2022).
- Price variations exist depending on payer negotiations and discounts.
- Insured and uninsured patients may face different cost shares, impacting reimbursement.
International Pricing
- European markets price Vistogard lower due to negotiated costs and formulary limits, averaging €15,000–€18,000 per course.
- Other markets vary and are dependent on local approval status and healthcare infrastructure.
Revenue Projections
Baseline Assumptions
- Conservative annual case volume: 1,500–2,000 US overdose treatments.
- Growth rate: 2%–3% annually, driven by increased awareness and expanded clinical protocols.
- Pricing remains stable but may decrease through generic entry or market pressure.
Projected Revenue (US Market)
| Year |
Treatment Volume |
Price per Course |
Estimated Revenue |
| 2022 |
1,500 |
$19,350 |
~$29 million |
| 2023 |
1,545 |
$19,350 |
~$29.9 million |
| 2024 |
1,591 |
$19,350 |
~$30.8 million |
| 2025 |
1,637 |
$19,350 |
~$31.7 million |
| 2026 |
1,684 |
$19,350 |
~$32.6 million |
Global Revenue Potential
- European, Asian, and other markets could constitute an additional 25% of US revenue, subject to regulatory approval timelines.
Market Challenges & Opportunities
Challenges
- Short treatment duration limits revenue per patient.
- Price sensitivity in public healthcare systems.
- Potential competition from off-label use of other agents or future therapies.
Opportunities
- Expansion into new indications, such as other chemotherapy overdose treatments.
- Market growth through increased awareness and clinical guideline updates.
- Potential licensing deals or manufacturer partnerships to expand global presence.
Regulatory and Policy Environment
- Continued reliance on FDA for approval extensions; no new formulations or derivatives expected soon.
- Reimbursement policies are influenced by the drug's emergency status and hospital formulary decisions.
- Legislation promoting rapid access to emergency antidotes may influence uptake.
Key Takeaways
- The drug’s narrow indication confines its market size; roughly 1,500–2,000 annual US treatments.
- Pricing at approximately $19,350 per course anchors revenue estimates of around $30 million annually in the US.
- Slight growth expected over the next five years, influenced by increasing awareness.
- International markets present growth opportunities but face pricing and regulatory hurdles.
- Market challenges include competition from off-label treatments and healthcare cost pressures.
FAQs
1. What is the primary driver of Vistogard’s market size?
The prevalence of chemotherapy regimens involving fluorouracil or capecitabine and the incidence of overdose cases requiring emergency treatment.
2. What factors could influence the drug’s price going forward?
Market competition, negotiation power of payers, changes in insurance reimbursement policies, and potential approval of generic versions.
3. How does international pricing compare to the US?
International prices are generally lower, averaging €15,000–€18,000 per course, impacted by regional healthcare policies and market dynamics.
4. What is the outlook for global expansion?
Approval in Europe and other regions could increase market size; however, delays in regulatory processes and pricing negotiations impact timelines.
5. Are there upcoming market threats or opportunities?
Potential threats include off-label substitutes and shifting reimbursement policies. Opportunities exist in expanding indications and global approval.
References
[1] SEER Program, National Cancer Institute, 2021.
[2] Johnson, R., & Cummings, S., 2018. "Overdose Management in Oncology," Journal of Clinical Oncology.
[3] MedPAC, 2022. "Pricing Trends for Specialty Drugs," Medicare Payment Advisory Commission.
